Am J Chin Med. COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease

[tetano]

Am J Chin Med. 2020 Mar 13:1-26. doi: 10.1142/S0192415X20500378. [Epub ahead of print]
COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease.


Chan KW¹, Wong VT², Tang SCW¹.

Author information




Abstract

As of 22 February 2020, more than 77662 cases of confirmed COVID-19 have been documented globally with over 2360 deaths. Common presentations of confirmed cases include fever, fatigue, dry cough, upper airway congestion, sputum production, shortness of breath, myalgia/arthralgia with lymphopenia, prolonged prothrombin time, elevated C-reactive protein, and elevated lactate dehydrogenase. The reported severe/critical case ratio is approximately 7-10% and median time to intensive care admission is 9.5-10.5 days with mortality of around 1-2% varied geographically. Similar to outbreaks of other newly identified virus, there is no proven regimen from conventional medicine and most reports managed the patients with lopinavir/ritonavir, ribavirin, beta-interferon, glucocorticoid and supportive treatment with remdesivir undergoing clinical trial. In China, Chinese medicine is proposed as a treatment option by national and provincial guidelines with substantial utilization. We reviewed the latest national and provincial clinical guidelines, retrospective cohort studies, and case series regarding the treatment of COVID-19 by add-on Chinese medicine. We have also reviewed the clinical evidence generated from SARS and H1N1 management with hypothesized mechanisms and latest in silico findings to identify candidate Chinese medicines for the consideration of possible trials and management. Given the paucity of strongly evidence-based regimens, the available data suggest that Chinese medicine could be considered as an adjunctive therapeutic option in the management of COVID-19.



KEYWORDS:

2019-nCoV; COVID-19; Chinese Medicine; Guideline; Integrative Medicine; Review


PMID:32164424DOI:10.1142/S0192415X20500378

[bertrand789]

Prescription classique. La cinqui?me ?dition de ?Standard Therapy of COVID-19? (abr?g?e Standard Therapy) publi?e le 9 f?vrier 2020, recommandait qu'une modification de la d?coction int?gr?e de Ma Xin Gan Shi avec Da Yuan Yin puisse ?tre utilis?e pour am?liorer la d?tresse thoracique, la toux et les sympt?mes asthmatiques qui se d?veloppent dans COVID-19 [ 12 ]. La d?coction de Ma Xin Gan Shi qui comprend Mahuang ( Ephedrae herba ), Xingren ( Armeniacae semen amarum ), Gancao ( Glycyrrhizae radix et rhizoma ), Shigao ( Gypsum fibrosum ) et Da Yuan Yin ont eu un impact significatif sur le SRAS en 2003 [ 41 , 42 ]. L'utilisation de Da Yuan Yin, compos? de Binlang ( semence Arecae), Houpo ( Magnoliae officinalis cortex ), Caoguo ( Tsaoko fructus ), Zhimu ( Anemarrhenae rhizoma ), Shaoyao ( Dioscoreae rhizoma ), Huangqin ( Scutellariae radix ), Gancao ( Glycyrrhizae raadix et rhizoma ), a ?t? enregistr? pour la premi?re fois ? Wen ( The Wen) de peste ) (1642 EC); cette d?coction est utilis?e pour traiter la peste depuis des milliers d'ann?es. L'efficacit? de cette d?coction pour le traitement du SRAS a ?t? ?valu?e ? l'aide d'une m?thode d'amarrage mol?culaire; la querc?tine, le kaempf?rol, la 7-m?thoxy-2-m?thyl isoflavone, la formonon?tine et la baicaleine ont ?t? identifi?s comme les cinq compos?s les plus connect?s ? la prot?ase SARS-CoV 3CL [ 43]. Un rapport dat? du 6 f?vrier 2020 de l'administration d'?tat de la m?decine traditionnelle chinoise a recommand? l'utilisation de la d?coction Qing Fei Pai Du qui comprend Mahuang ( Ephedrae herba ), Shigao ( Gypsum fibrosum ), Banxia ( Pinelliae rhizoma ), Zhishi ( Aurantii fructus immaturus ) , D?coctions de Shengjiang ( Zingiberis rhizoma recens ), d?riv?es d'une modification de l'int?gration des d?coctions de Ma Xing Gan Shi, She Gan Ma Huang, Xiao Chai Hu et Wu Ling San dans Shang Han Za Bing Lun ( Trait? sur les maladies par dommages froids)) (200 CE-210 CE); cette recommandation ?tait bas?e sur l'exp?rience ant?rieure avec le SRAS et le temps froid et humide ? Wuhan. Il a ?t? d?montr? que la d?coction Qing Fei Pai Du est efficace ? 90% dans le traitement de COVID-19
https://www.tmrjournals.com/tmr/arti...3-5-2-65.shtml

[Frozenthunderbolt]

full text:sci-hub.se/10.1142/S0192415X20500378